drugset / Trial / NCT06243198
A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants
RandomizedSequentialDouble-blindBasic science
Summary
The main purpose of this study is to determine the tolerability and side effects related to lebrikizumab comparing with placebo given as a single dose administered under the skin to healthy Chinese participants. The study will also assess how fast lebrikizumab gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either Lebrikizumab or placebo. For each participant, the total duration of the study will be approximately up to 21 weeks, including screening period.
Timeline
- Start
- 2024-03-28
- Primary completion
- 2024-09-03
- Completion
- 2024-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lebrikizumab | Monoclonal antibody | 250 mg | Subcutaneous |
| Subject | Lebrikizumab | Monoclonal antibody | 500 mg | Subcutaneous |
Indications
No indication recorded.